Next Article in Journal
Insights into Biological Role of LncRNAs in Epithelial-Mesenchymal Transition
Next Article in Special Issue
Conditional Reprogramming for Patient-Derived Cancer Models and Next-Generation Living Biobanks
Previous Article in Journal
The Incomplete Puzzle of the BCL2 Proteins
Previous Article in Special Issue
Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines
Open AccessReview

Patient-Derived Glioma Models: From Patients to Dish to Animals

1
Experimental Therapeutics and Molecular Imaging Laboratory, Department of Neurology, Neuro-Oncology Division, Massachusetts General Hospital, Boston, MA 02129, USA
2
Neuroscience Program, Harvard Medical School, Boston MA 02129, USA
3
Department of Neurosurgery, Cancer Center Amsterdam, Brain Tumor Center Amsterdam, Amsterdam UMC, Vrije Universiteit Medical Center, 1081 HV Amsterdam, The Netherlands
*
Author to whom correspondence should be addressed.
These authors contributed equally to this paper.
Cells 2019, 8(10), 1177; https://doi.org/10.3390/cells8101177
Received: 30 July 2019 / Revised: 13 September 2019 / Accepted: 27 September 2019 / Published: 30 September 2019
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults associated with a poor survival. Current standard of care consists of surgical resection followed by radiation and chemotherapy. GBMs are highly heterogeneous, having a complex interaction among different cells within the tumor as well as the tumor microenvironment. One of the main challenges in the neuro-oncology field in general, and GBM in particular, is to find an optimum culture condition that maintains the molecular genotype and phenotype as well as heterogeneity of the original tumor in vitro and in vivo. Established cell lines were shown to be a poor model of the disease, failing to recapitulate the phenotype and harboring non-parental genotypic mutations. Given the growing understanding of GBM biology, the discovery of glioma cancer stem-like cells (GSCs), and their role in tumor formation and therapeutic resistance, scientists are turning more towards patient-derived cells and xenografts as a more representative model. In this review, we will discuss the current state of patient-derived GSCs and their xenografts; and provide an overview of different established models to study GBM biology and to identify novel therapeutics in the pre-clinical phase. View Full-Text
Keywords: glioblastoma; cancer stem cells; patient-derived xenograft model; 3D cultures; organoids glioblastoma; cancer stem cells; patient-derived xenograft model; 3D cultures; organoids
Show Figures

Figure 1

MDPI and ACS Style

da Hora, C.C.; Schweiger, M.W.; Wurdinger, T.; Tannous, B.A. Patient-Derived Glioma Models: From Patients to Dish to Animals. Cells 2019, 8, 1177.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop